Cumberland Pharmaceuticals Stock Rating Upgraded

Wall Street Zen analysts raise CPIX rating to 'buy' from 'hold'

Mar. 16, 2026 at 5:08am

Got story updates? Submit your updates here. ›

Cumberland Pharmaceuticals (NASDAQ:CPIX), a specialty pharmaceutical company based in Nashville, Tennessee, has had its stock rating upgraded by analysts at Wall Street Zen. The analysts raised their rating on CPIX shares from 'hold' to 'buy' in a research note issued on Saturday. Separately, Weiss Ratings maintained a 'sell (d-)' rating on Cumberland Pharmaceuticals stock.

Why it matters

The stock rating upgrade from Wall Street Zen could signal increased investor confidence in Cumberland Pharmaceuticals and its portfolio of hospital and acute care products. As a specialty pharmaceutical company, Cumberland's performance and outlook are closely watched by investors in the sector.

The details

Cumberland Pharmaceuticals focuses on the development, manufacture and commercialization of hospital and acute care products. The company's flagship products include Acetadote, Vasostrict, Cerebrex and Dynastat. Wall Street Zen analysts cited Cumberland's product portfolio and market positioning in upgrading the stock to a 'buy' rating, while Weiss Ratings maintained a 'sell' recommendation.

  • The Wall Street Zen rating upgrade was issued on Saturday, March 16, 2026.
  • Weiss Ratings maintained its 'sell (d-)' rating on Cumberland Pharmaceuticals stock on Monday, December 29th.

The players

Cumberland Pharmaceuticals Inc

A specialty pharmaceutical company based in Nashville, Tennessee, focused on developing, manufacturing and commercializing hospital and acute care products.

Wall Street Zen

A financial research and analysis firm that upgraded its rating on Cumberland Pharmaceuticals stock from 'hold' to 'buy'.

Weiss Ratings

A financial research firm that maintained its 'sell (d-)' rating on Cumberland Pharmaceuticals stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The stock rating upgrade from Wall Street Zen reflects growing investor confidence in Cumberland Pharmaceuticals and its portfolio of hospital and acute care products. As a specialty pharmaceutical company, Cumberland's performance and outlook are closely watched by investors in the sector.